Therapy for Chronic Cold Agglutinin Disease
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Rituximab
Related studies linked through entity extraction aliases.
Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Pilot Study of Rituximab for the Treatment of Acute Immune Thrombocytopenic Purpura (ITP)
- Status
- COMPLETED
- Phase
- PHASE2
Trial of Rituximab Given Pre-Transplant to Sensitised Live Donor Kidney Recipients
- Status
- UNKNOWN
- Phase
- PHASE2
Trial of VELCADE and Rituxan as Front-line Tx for Low-grade NHL
- Status
- COMPLETED
- Phase
- PHASE2
Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Lower But More Frequent Dose Rituximab to Treat Chronic Lymphocytic Leukemia
- Status
- COMPLETED
- Phase
- PHASE1
Initial Study of Rituximab to Treat Primary Biliary Cirrhosis
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Ph II CHOP+Velcade in Mediastinal LBCL
- Status
- TERMINATED
- Phase
- PHASE2
A Phase 2 Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft Versus Host Disease
- Status
- COMPLETED
- Phase
- NA
Rituximab in Primary Lymphocyte Predominant Hodgkin´s Disease(RIPL)
- Status
- COMPLETED
- Phase
- PHASE2
Cyclophosphamide and Rituximab Followed By Vaccine Therapy in Treating Patients With Chronic Lymphocytic Leukemia
- Status
- WITHDRAWN
- Phase
- PHASE2
Combination Chemotherapy With or Without Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status.
- Status
- UNKNOWN
- Phase
- PHASE2
Rituximab to Treat Severe Hemophilia A
- Status
- COMPLETED
- Phase
- PHASE2
Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL
- Status
- COMPLETED
- Phase
- PHASE1
Treatment of Acute Lymphoblastic Leukemia (ALL) in Younger Adults
- Status
- COMPLETED
- Phase
- PHASE3
GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
- Status
- SUSPENDED
- Phase
- PHASE3